HealthAI imageFDA Approves Fayuvi Gene Therapy, RARE Stock Jumps 13%
The FDA granted full approval to Fayuvi (UX111), a gene therapy for pediatric patients with Sanfilippo syndrome. Following the approval, RARE stock surged 13% and extended gains in after-hours trading. This marks a significant milestone for the treatment of this rare genetic disorder affecting children.
Asianet Newsable·




